Articles tagged with Liver
Comprehensive exploration of living organisms, biological systems, and life processes across all scales from molecules to ecosystems. Encompasses cutting-edge research in biology, genetics, molecular biology, ecology, biochemistry, microbiology, botany, zoology, evolutionary biology, genomics, and biotechnology. Investigates cellular mechanisms, organism development, genetic inheritance, biodiversity conservation, metabolic processes, protein synthesis, DNA sequencing, CRISPR gene editing, stem cell research, and the fundamental principles governing all forms of life on Earth.
Comprehensive medical research, clinical studies, and healthcare sciences focused on disease prevention, diagnosis, and treatment. Encompasses clinical medicine, public health, pharmacology, epidemiology, medical specialties, disease mechanisms, therapeutic interventions, healthcare innovation, precision medicine, telemedicine, medical devices, drug development, clinical trials, patient care, mental health, nutrition science, health policy, and the application of medical science to improve human health, wellbeing, and quality of life across diverse populations.
Comprehensive investigation of human society, behavior, relationships, and social structures through systematic research and analysis. Encompasses psychology, sociology, anthropology, economics, political science, linguistics, education, demography, communications, and social research methodologies. Examines human cognition, social interactions, cultural phenomena, economic systems, political institutions, language and communication, educational processes, population dynamics, and the complex social, cultural, economic, and political forces shaping human societies, communities, and civilizations throughout history and across the contemporary world.
Fundamental study of the non-living natural world, matter, energy, and physical phenomena governing the universe. Encompasses physics, chemistry, earth sciences, atmospheric sciences, oceanography, materials science, and the investigation of physical laws, chemical reactions, geological processes, climate systems, and planetary dynamics. Explores everything from subatomic particles and quantum mechanics to planetary systems and cosmic phenomena, including energy transformations, molecular interactions, elemental properties, weather patterns, tectonic activity, and the fundamental forces and principles underlying the physical nature of reality.
Practical application of scientific knowledge and engineering principles to solve real-world problems and develop innovative technologies. Encompasses all engineering disciplines, technology development, computer science, artificial intelligence, environmental sciences, agriculture, materials applications, energy systems, and industrial innovation. Bridges theoretical research with tangible solutions for infrastructure, manufacturing, computing, communications, transportation, construction, sustainable development, and emerging technologies that advance human capabilities, improve quality of life, and address societal challenges through scientific innovation and technological progress.
Study of the practice, culture, infrastructure, and social dimensions of science itself. Addresses how science is conducted, organized, communicated, and integrated into society. Encompasses research funding mechanisms, scientific publishing systems, peer review processes, academic ethics, science policy, research institutions, scientific collaboration networks, science education, career development, research programs, scientific methods, science communication, and the sociology of scientific discovery. Examines the human, institutional, and cultural aspects of scientific enterprise, knowledge production, and the translation of research into societal benefit.
Comprehensive study of the universe beyond Earth, encompassing celestial objects, cosmic phenomena, and space exploration. Includes astronomy, astrophysics, planetary science, cosmology, space physics, astrobiology, and space technology. Investigates stars, galaxies, planets, moons, asteroids, comets, black holes, nebulae, exoplanets, dark matter, dark energy, cosmic microwave background, stellar evolution, planetary formation, space weather, solar system dynamics, the search for extraterrestrial life, and humanity's efforts to explore, understand, and unlock the mysteries of the cosmos through observation, theory, and space missions.
Comprehensive examination of tools, techniques, methodologies, and approaches used across scientific disciplines to conduct research, collect data, and analyze results. Encompasses experimental procedures, analytical methods, measurement techniques, instrumentation, imaging technologies, spectroscopic methods, laboratory protocols, observational studies, statistical analysis, computational methods, data visualization, quality control, and methodological innovations. Addresses the practical techniques and theoretical frameworks enabling scientists to investigate phenomena, test hypotheses, gather evidence, ensure reproducibility, and generate reliable knowledge through systematic, rigorous investigation across all areas of scientific inquiry.
Study of abstract structures, patterns, quantities, relationships, and logical reasoning through pure and applied mathematical disciplines. Encompasses algebra, calculus, geometry, topology, number theory, analysis, discrete mathematics, mathematical logic, set theory, probability, statistics, and computational mathematics. Investigates mathematical structures, theorems, proofs, algorithms, functions, equations, and the rigorous logical frameworks underlying quantitative reasoning. Provides the foundational language and tools for all scientific fields, enabling precise description of natural phenomena, modeling of complex systems, and the development of technologies across physics, engineering, computer science, economics, and all quantitative sciences.
A new therapy with high cure rates is available, but the high cost of direct acting antiviral (DAA) treatment limits access for many hepatitis C virus patients. Increasing treatment efficacy and accessibility could avert significant liver-related deaths and end-stage liver disease in Australia.
A new class of protein-based contrast agents (PRCAs) has been developed to detect liver cancer at an early stage, providing robust results. The agent, ProCA32, allows for imaging of liver tumors measuring less than 0.25 millimeters with improved sensitivity and accuracy compared to existing methods.
A new study found that liver transplant centers in highly competitive geographic areas performed more transplants than those in less competitive areas. The researchers used data from 53,156 adult liver transplantation operations performed between 2003 and 2012.
Researchers at University College London have found that hepatitis B virus can persist in the liver by exploiting starved T cells. The study suggests that boosting the immune system and counteracting the liver's suppressive effect could potentially clear the infection.
Researchers successfully restored bilirubin levels to those found in healthy animals using gene therapy, offering new hope for the treatment of Crigler-Najjar syndrome. The therapy involved transferring a copy of the UGT1A1 gene into liver cells using an AAV vector, resulting in long-term correction without immunosuppression.
A plant toxin has been found to cause biliary atresia, a rare and debilitating liver disease, in animal models. The toxin, isolated from Australian plants, selectively destroys the bile ducts outside the liver, leading to scarring and preventing bile flow.
A 12-week dose of an investigational three-drug combination cleared the virus in 93 percent of patients with liver cirrhosis who hadn't previously been treated. The addition of ribavirin to the regimen enhanced results, eliminating the virus in 93 percent of previously treated patients.
A new study found that living liver donors experienced lower sexual function at evaluation phase and three months after surgery. Donor education prior to surgery may help ease concerns and improve recovery.
A study found that using a pocket-sized ultrasound device (PUD) with physical examination can improve diagnosis accuracy and reduce the number of tests needed. The PUD was found to be comparable in performance to standard ultrasonography, but improved the accuracy of physical examinations, resulting in a 37% reduction in further testing.
The study found that the Sofosbuvir/daclatasvir combination achieved an 81.6% SVR4 rate after 12 weeks of treatment and a 93.9% SVR4 rate after 24 weeks, with a 100% SVR4 rate when combined with ribavirin. The treatment was effective in both cirrhotic and non-cirrhotic patients.
A comprehensive review highlights the need for better evidence on hepatitis B and C testing in European countries. The study found gaps in knowledge, particularly for high-risk populations such as migrants and men who have sex with men.
A study reveals that individuals with undiagnosed hepatitis C infection have a similar risk of developing advanced liver fibrosis as those who are diagnosed. The findings support the importance of regular screening for HCV, especially in high-risk groups.
A phase 3 study showed that a combination of daclatasvir, sofosbuvir, and ribavirin was effective in achieving sustained virologic response rates of over 90% in patients with HCV infection and advanced cirrhosis. The treatment was also well-tolerated, with no serious treatment-related side effects.
A worldwide study shows that daily drinking is a significant predictor of liver disease burden, with heavy drinkers having the highest risk. The study highlights the need for reducing heavy drinking as an important target for public health monitoring and policies.
A Phase 3 study demonstrates that sofosbuvir in combination with ribavirin and peginterferon is highly effective for treating genotype-3 HCV-infected patients, particularly those with cirrhosis. The BOSON study shows the optimal duration of treatment for these patients, which could lead to improved outcomes.
A recent study published in The International Liver Congress shows that alcohol use disorders are a stronger predictor of mortality than chronic hepatitis C virus infection, especially when severe comorbidities are present. AUDs were found to be associated with higher mortality risks across all hospital subgroups.
A new study presented at The International Liver Congress 2015 showed high rates of sustained virologic response and good tolerance when using sofosbuvir and daclatasvir-based regimens in patients with recurrent hepatitis C. These results support the use of interferon-free regimens in managing liver transplant patients infected with HCV.
The RUBY-1 study evaluates ombitasvir/paritaprevir/ritonavir and dasabuvir in patients with stage 4 or 5 CKD and HCV GT1 infection, revealing a well-tolerated combination with rapid viral load suppression.
BLU-554, a small molecule inhibitor of FGFR4, has been identified as a potential treatment option for up to 30% of HCC patients. The investigational drug was shown to be potent and 'exquisitely selective' for FGFR4 compared to other kinases targeting the FGFR family.
A 12-week oral regimen of once-daily single tablet grazoprevir/elbasvir is effective and well-tolerated in treatment-naive patients infected with chronic hepatitis C virus (HCV) genotypes 1, 4 or 6. Preliminary results show that 299 out of 316 patients achieved a sustained virologic response at 12 weeks.
A large population-based cohort study found that non-alcoholic steatohepatitis (NASH) increases the risk of death by 50% compared to non-alcoholic fatty liver disease (NAFLD). The study also showed that patients with NASH had a higher risk of cardiovascular disease and all-cause mortality over a 14-year period.
The study demonstrated that ledipasvir-sofosbuvir achieves high sustained virologic response rates in patients with chronic genotype 4 and 5 HCV infection. The treatment was found to be effective in both treatment-naive and treatment-experienced patients, with similar SVR12 rates across all patient types.
Many European countries lack national strategies to manage chronic viral hepatitis disease surveillance, burden assessment, and intervention impact. Governments need support for developing plans, estimating the national burden, and improving surveillance systems.
The daclatasvir-sofosbuvir combination was highly effective and well-tolerated in treating hepatitis C virus (HCV) patients with HIV co-infection. Across genotypes 1-4, the treatment resulted in a sustained virologic response rate of 97% at 12 weeks post-treatment.
The HCV-TARGET study shows all-oral direct-acting antiviral therapy is highly effective and well tolerated in patients with decompensated cirrhosis, with SVR rates of 75%, 77% and 81%. Liver function markers also improve during short-term follow-up.
A new study published at The International Liver Congress reveals that non-alcoholic fatty liver disease (NAFLD) is associated with the development of coronary artery calcification. In patients without existing CAC, NAFLD significantly accelerated atherosclerosis progression, while in those with existing CAC, it did not affect disease ...
A new study at The International Liver Congress 2015 reveals that sofosbuvir-based regimens are effective and well-tolerated in hepatitis C and HIV co-infected, cirrhotic patients. Sustained virologic response was observed in 98% of patients at 4 weeks and 95% at 12 weeks.
A new device has demonstrated its potential to preserve and improve the quality of donor livers from donation after circulatory death (DCD) for transplantation. The transportable machine perfusion Airdrive effectively maintained liver quality, reducing biliary complications and increasing graft function.
A new survey found that nearly half of people with viral hepatitis have suffered some kind of discrimination, affecting their daily lives. The study highlights the devastating impact of stigma and discrimination on quality of life, particularly in family relationships and workplaces.
TG1050 has been shown to reach the clinical goals considered a cure for CHB, including elimination of HBsAg and seroconversion. The study achieved these goals in 30% of TG1050-injected mice, supporting the move to a first-in-man study.
A study has demonstrated that alginate-enriched bread can inhibit fat digestion and circulatory lipids in patients with non-alcoholic fatty liver disease (NAFLD). The results show a significant reduction of up to 31% in fat digestion, suggesting its potential use as a therapeutic weight management therapy.
A study published by the European Association for the Study of the Liver found that silymarin, derived from milk thistle, can resolve non-alcoholic steatohepatitis (NASH) and improve fibrosis in patients. The results suggest a potential new treatment option for this condition.
A pooled analysis of data from two randomized trials confirms vitamin E as an effective treatment for non-alcoholic steatohepatitis (NASH), with significant improvements in liver histology and disease resolution. The study supports the use of vitamin E as a safe and effective solution for both adults and children with NASH.
Scaling up existing interventions, including infant vaccination and treatment programmes, could prevent 90% of new chronic HBV infections and 65% mortality levels by 2030. Global expansion is necessary to achieve hepatitis B elimination, avoiding 20 million deaths by 2030.
A new study reveals that chronic hepatitis C virus (HCV) infection is associated with a higher risk of developing cardiovascular diseases. The study found significant increases in the cost of care and length of time in hospital for patients with HCV infections.
Remogliflozin etabonate improves insulin sensitivity and beta cell function, reducing ALT levels and weight in patients with NASH. The investigational drug also exhibits intrinsic anti-oxidant activity, reversing steatohepatitis and oxidative stress.
A large cohort study found that long-term use of entecavir (ETV) or tenofovir (TDF) results in excellent 5-year survival for Caucasian patients with chronic hepatitis B (CHB), with a significant proportion of deaths coming from liver-unrelated causes. The development of hepatocellular carcinoma plays a major role in mortality.
A new study presented at The International Liver Congress 2015 shows that significant weight loss through lifestyle changes can improve histological features of non-alcoholic steatohepatitis (NASH). Over 10% weight loss is necessary to induce complete resolution of steatohepatitis, fibrosis, and portal inflammation.
A new study shows that Baclofen has a positive impact on alcohol consumption and liver function in patients with alcohol-induced liver disease. The results demonstrate improved indicators of liver health, reduced physical dependence, and lower standard measures of liver damage.
Results from the SOLAR 2 trial show that ledipasvir/sofosbuvir in combination with ribavirin is safe and effective in patients with decompensated liver disease or who have undergone liver transplantation. High sustained virologic response rates were achieved, even among treatment-experienced patients.
Researchers found that delaying treatment until after a patient's FIB4 level exceeds 3.25 has a clear detrimental effect on treatment effectiveness, increasing morbidity and mortality risks. Early treatment initiation is crucial to prevent adverse outcomes.
Researchers identified specific molecular profiles and mutational patterns that can help determine which hepatocellular carcinoma patients benefit from targeted anticancer treatments. The study suggests that exome sequencing can be used to identify potential new targets for therapy, leading to optimized personalized patient care.
Capsaicin, the active compound in chili peppers, has been found to have beneficial effects on liver damage. In a study, capsaicin reduced the activation of hepatic stellate cells, which are involved in liver fibrosis. The compound partially improved liver damage and inhibited further progression of the injury in mice models.
A randomized controlled trial demonstrated liraglutide met the primary endpoint of histological clearance of non-alcoholic steatohepatitis, and a reduction in fibrosis progression. The study also showed significant weight loss, BMI reduction, and fasting glucose decrease with liraglutide treatment.
Preliminary results show that Civacir effectively prevents hepatitis C virus (HCV) recurrence in liver transplant patients who received antiviral therapy before their operation. The study found that Civacir provides a prophylactic efficacy in preventing HCV-reinfection, reducing the risk of graft loss.
Recent studies confirm that NAFLD worsens heart disease and increases serum levels of cardiovascular risk markers. Additionally, a large population sample found a significant association between psychological distress and liver disease mortality. Meanwhile, inpatient mortality for cirrhosis patients has decreased by 41% in the U.S., at...
A new study found a significant decline in hospital mortality rates among patients with cirrhosis and liver failure. The study analyzed over 780,000 hospitalizations and found that inpatient mortality decreased steadily during the period, despite increases in patient age and medical complexity.
A major study published in the New England Journal of Medicine found that treatments for alcoholic hepatitis, including prednisolone and pentoxifylline, are ineffective at increasing patient survival. The study involved over 1,000 patients and found that mortality rates remained high despite treatment.
Researchers at RIKEN have developed a novel method for preserving donor livers, significantly extending their viability and improving transplant outcomes. By cooling organs to 22°C and supplementing with red blood cells, the team achieved remarkable success rates, even with organs obtained after cardiac arrest.
A study found that female liver cells are more susceptible to adverse effects of drugs than male counterparts, particularly postmenopausal women. The findings highlight the need for a sex-specific approach in toxicology and suggest that current theories cannot explain why women are generally more sensitive to drug toxicity.
Researchers created a mouse model showing telomere dysfunction triggers liver damage, including cirrhosis and hepatitis. Telomeres protect genetic data, but their dysfunction leads to disease.
A large-scale genome-wide association study found that men whose fathers had liver disease are more likely to develop alcoholic cirrhosis. The study, published in Alcoholism: Clinical & Experimental Research, suggests that genetic factors may play a role in this increased risk.
A new study finds that effective new hepatitis C drugs are extremely costly, with some treatments costing between $94,500 and $189,000. The state of Rhode Island would need to spend almost twice its entire prison health budget to treat all its chronically infected inmates.
A new study found that combining traditional assessment tools with data from nurses' assessments significantly improves the ability to predict survival in cirrhosis patients. This may help improve patient outcomes by identifying patients who can benefit from rehabilitation and intensifying their nutritional support.
A new study published in the Journal of Hepatology shows that exercise, regardless of frequency or intensity, benefits obese and overweight adults with non-alcoholic fatty liver disease (NAFLD). Both aerobic and resistance training-based exercise regimens reduce liver fat and visceral fat. The improvement was independent of weight loss.
Research links non-alcoholic steatohepatitis (NASH) with increased intestinal permeability, suggesting a 'gut-liver axis' role in its development. The study found that liver injury may precede changes in gut permeability, potentially worsening liver disease.
A computer model developed by scientists can predict how the liver stores fat in response to various situations, including drug treatment. This knowledge could help researchers understand and treat diseases, as well as develop new drugs with fewer side effects.
Researchers at UC Davis found that fibroblast growth factor 21 (FGF21) can boost the regenerative effects of human PPARα, allowing it to regenerate damaged livers in mice. The protein could offer significant therapeutic benefits for patients with liver disease or those who have had a liver transplant.
Paracetamol is ineffective in reducing pain, disability, or improving quality of life for patients with low back pain or osteoarthritis. Its use may also affect the liver, increasing the risk of liver toxicity in patients. The study calls for an urgent review of guidelines that endorse paracetamol for these conditions.
A study from the University of Eastern Finland found that risk factor levels even below accepted thresholds can be harmful when several risk factors cluster. Clustered risk factors were linked to elevated liver enzymes in overweight children, particularly those with a common PNPLA3 gene mutation.